The global GLP-1 Receptor Agonist Market was valued at USD 66.4 billion in 2025 and is projected to grow from USD 82.0 billion in 2026 to USD 185.3 billion by 2033, registering a CAGR of 12.4% from 2026 to 2033. The market is witnessing remarkable growth due to the rising prevalence of type 2 diabetes, obesity, and other metabolic disorders, coupled with increasing clinical acceptance...

According to a new report from Intel Market Research, the global diabetes drugs market was valued at USD 99,880 million in 2024 and is projected to grow from USD 108,000 million in 2025 to USD 218,800 million by 2032, exhibiting a robust CAGR of 12.1% during the forecast period (2025–2032). This growth is driven by the rising global prevalence of diabetes, increased healthcare...

According to a newly published market research report by 24LifeSciences, global ultra long acting insulin market was valued at USD 15.2 billion in 2025 and is projected to reach USD 24.8 billion by 2034, growing at a compound annual growth rate (CAGR) of 5.7% during the forecast period 20262034. Ultra long acting insulin represents the most advanced form of basal insulin therapy, providing...

The US Diabetes Drug Therapy Market holds a significant position globally, supported by a high prevalence of diabetes, strong healthcare spending, and widespread adoption of advanced treatment options. The increasing use of innovative drug classes, including GLP-1 receptor agonists, SGLT2 inhibitors, and next-generation insulin therapies, is driving market growth across the country. Favorable...